Abstract This paper analyzes the Minister of Health's (MoH) 
Introduction
Every year around 1.4 million deaths occur worldwide due to causes related to viral hepatitis 1 . An estimated 500 million people are living with chronic hepatitis B and C virus infection. Viral hepatitis has been considered an invisible epidemic that affects all countries irrespective of income level.
In 2010, the World Health Assembly (WHA) recognized viral hepatitis as a global public health problem (WHA 63.18) 1 . In 2012, the World Health Organization (WHO) proposed a plan of action for the prevention, health care and control of viral hepatitis in order to raise awareness about the problem 1 . At the 2014 WHA a new resolution was approved, urging all WHO Member States to adopt and/or strengthen appropriate actions to prevent transmission of the six types of hepatites virus, as well as to provide appropriate care / treatment to those in need 2 .
The clinical presentation, severity and disease progression or not to chronic liver disease, depends on the type of virus involved, as well as on the actions implemented to control and treat the infection. Hepatitis A, B and C are the most prevalent types in the world. The first is transmitted by ingestion of water or food contaminated with fecal material. Hepatitis B can be transmitted through unprotected sexual intercourse and/or blood contact from an infected person, and may progress to chronic forms of liver disease. Hepatitis C is mainly transmitted through contact with contaminated blood and usually evolves quietly to chronic hepatitis. There are effective vaccines for hepatitis A and B, but not for hepatitis C 3 . Hepatitis B can be transmitted through sexual or blood contact with an infected person. It may progress to chronic forms of liver disease. Hepatitis C is mainly transmitted through contact with contamineted blood and usually evolves quietly and slowly to chronic hepatitis.
Chronic hepatitis B and C should be treated with medicines that suppresses viral replication, which reduces the disease progression to more severe outcomes, such as cirrhosis and liver carcinoma.
Since the 1980s, viral hepatitis have been apriority for health authorities in Brazil. From 1996, viral hepatitis is acompulsory notifiable disease to SINAN (National System for Diseases Surveillance. This is a key information source for MoH authorities to design policies for prevention, treatment and control of hepatitis 4, 5 . Since 1998, in addition to actions aimed at structuring the network of diagnostic and treatment health services, universal vaccination against hepatitis B has been established. Initially, all newborns and children under one year of age were vaccinated. Currently vaccination covers all persons under 49 years-old.
Initially, the treatment provided for Hepatitis C was conventional alfainterferon 2a and 2b monotherapy. These medicines used to be purchased by the Brazilian states and co-financed by the MoH 4 . Then, the treatment protocol adopted also included a combined treatment regimen with peginterferon alfa 2aor 2b plus an antiviral 6, 7 . In 2000, the first clinical guideline for hepatitis C was published, which recommended the use of dual peginterferon 2a or 2b plus ribavirin regimen 8 . In 2002, the National Program for the Control of Viral Hepatitis was established (Ordinance MS263 / 2002) 9, 10 . In 2009 the program was incorporated into the Department of Sexually Transmitted Diseases, Aids and Viral Hepatitis 11 . Currently the treatment of hepatitis C is undergoing an important transformation, in which new medicines, known as direct-acting antiviral drugs (DAA), administered orally, are available or are in final stages of development (clinical studies) 12 . In May 2015, WHO included five DAAs in its Model List of Essential Medicines 13 , which has been a guide to decision-makers at country-level. They are sofosbuvir, simeprevir, daclatasvir, desabuvir and the fixed dose combinations ledipasvir + sofosbuvir and ombitasvir paritaprevir + ritonavir.
These medicines are under monopoly, because pharmaeutical companies have applied for patent protection in different countries 14 , in the widespread global adoption of intelectual property protection under the Agreement on Trade Related Aspects of Intellectual Property Rights of the World Trade Organization (WTO TRIPS Agreement). Patent protection of products may occur in almost every country in the world including those with the ability to produce generic versions. Thus, these companies are in a position to define prices. The huge potential lucrative global market is the main factor that has driven the development of the new DAAs. The price of these new medicines challenges the ability to purchase of developed and developing countries and their capacity to respond to the epidemic as set out in international commitments 15, 16 . Thefere, treatment of hepatitis C is a model case study of the incorporation of monopoly products into public and private health systems, in which the increasing costs threatens the sustainability of policies to ensure access to treatment. India in 2016 was US$ 183 for 12 weeks of treatment 22 . No reference price information for daclatasvir previous years was found 2016. For the SOF + SIM combination the price paid in Brazil in 2015 for SIM (US$ 2,426 for 12 weeks of treatment) was used and the three above mentioned price options for SOF. No international reference price was found for SIM generic version.
Results
There was a 159. Two new medicines introduced in 2012, telaprevir and boceprevir, had contracted expenses of R$ 298,283.9 million, which corresponded to 99.9% of the total purchases of the MoH for hepatitis C medicines that year (Graph 1). This result illustrates the burden of these medications on the MoH expenditure. In 2013, there was a 34.7% reduction in spending for hepatitis C compared to Alfa interferon 2a, 3,000,000 UI e 9,000,000 UI, injectable solution Alfa interferon 2b, 5,000,000 UI e 10,000,000 UI injectable solution 
Discusion
This study demonstrates that during the study period there was an increase in MoH spending for hepatitis C treatments. The data shows that the increase was initially due to the centralization of the purchases and incorporation of peginterferon, and later, due to the incorporation of new DAAs. There was an increase in the volume of pharmaceutical units acquired over time, but also 22 . The increase in volume and expenditure of purchases in 2005 and 2006 shows the burden of the incorporation of peginterferon for the treatment of hepatitis C. As shown in Chart 2, the volume of purchases of peginterferon became higher in subsequent years, when compared to purchases of conventional INF, suggesting a preference for the first option over the second, and illustrating the effect of incorporation of new medical technologies. In the same period, there was a reduction in the direct cost of treatment, due to the price of the therapeutic regimen adopted. Thus, even with the increase in the volume of purchases, the total expenses did not increase.This suggests that the centralization of purchasing had a positive effect on the reduction of the unit price of peginterferon 2a and 2b.
Centralized procurement, as happened for ARV 24 and imatinib mesylate 25 , was an important strategy for reducing the price of alfa peginterferon in a context of increasing access to treatment in the country, probably due to the stronger bargain power of the MoH given its capacity to purchase greater volume of medicines 26 .
Moreover, the significant reduction in the cost of treatment with peginterferon (Graph 2) may reflect some strategies adopted by the MoH such as: better price negotiation with manufacturing companies; Competition between the two peginterferon options; and the expectation that a new DAA will be launched in the international market. Alfa peginterferon 2a is supplied by Roche and 2b by Shering-Plough. As there is no therapeutic difference between between alfa peginterferon 2a and 2b, the difference occurs in the number of units administered, which is greater for the 2b because of the differences in concentration.
In the case under analysis it can be assumed that the lower unit price, together with the purchased volume (70%) of alfa peginterferon 2a, in 2011, may have influenced the price reduction verified in 2013 for peginterferon 2b. , and pointing to an interferon-free therapy scenario. From the use perspective, the new DAAs favor treatment, because they are orally administrated and shorter duration of treatment, for example 12 weeks, than previous regimens using interferon. Changes in treatment regimens and their effects are highlighted in two moments, marked respectively by the incorporation of peginterferon in 2005 and the DAAs in 2012, when there was a significant increase in MoH expenditure. In the first, the benefit in improved patients adherence to treatment due to reduction in the number of doses administered (from 3 times a week with conventional alfa interferon to one time a weel with alfa-peginterferon). In 2012, the incorporation of two DAAs -boceprevir and telaprevir -for the treatment of hepatitis C cases with advanced fibrosis, and not responsive to the previous regimens, accounted for 98% of purchases that year. Compared with the previous regimen, the increase observed in the individual cost of treatment (Graph 2) was significant and has considerably changed the profile of MoH spending on hepatitis C as of 2012.
According to the 2013 17 MoH guidelines, treatment with telaprevir and bocepreviris indicated only forhepatitis C patients with advanced stages of liver disease (metavir F3 and F4). In 2012 the purchase of great quantity of these medicines resulted in significant increase of the MoH expenditure. This is because between 2012 and 2014, as shown in Graph 1, the purchase of these two DAA accounted for almost all of the financial resources available for hepatitis C medicines. In 2012, the volume measured by the number of treatments purchased were 1,255 and 4,257 treatments for boceprevir and telaprevir respectively. This may mean that the number of patients eligible for treatment with these DAAs in the country was probably higher due to late detection of the disease.
In 2015, treatment options were further amended, when the National Commission for the Incorporation of Technologies in SUS (Conitec) approved the incorporation of sofosbuvir, simeprevir, daclatasvir, and reccomended the adoption of interferon-free regimens for specific cases such as advanced hepatic fibrosis (metavir F3 or F4); F2 liver biopsy for more than three years; HIV / HCV coinfection; pre and post transplantation of liver and other specific indications 28 .
The purpose of incorporation is to ensure the best treatment for all. When Conitec recommends incorporation, it does not limit its analysis to therapeutic evidence; it also examines the impact of technology on the health system, considering the need to ensure treatment for those who need it. The incorporation of the technology must be linked to the therapeutic guidelines, for two reasons: first, the therapeutic guidelines that, according to the WHO, supports the medicine indication and therefore its selection; Secondly, because the Brazilian Decree 7,508/12 establishes that medicines within the SUS should be prescribed according to existing therapeutic guidelines 29 . The incorporation of the DAAs led to the revision of the PCDT in 2015 20 .
Once the effectiveness of interferon-free regimens was confirmed, it is essential that they are guaranteed for all, because they are treatments with high success rates and cure a slow-onset disease but with high morbidity rates 28 . In relation to prices, the process of purchasing medicines for hepatitis C should consider the dynamics of the medicines marketing, production and patent issues. Moreover, the market dynamics for these medicines in developing countries points to opportunities for price reduction. In Brazil, the treatment costs for the combinations of sofosbuvir + simeprevir and sofosbuvir + daclatasvir were in 2015 respectively US $ 8,803 and US $ 8,732. The MoH claims to have achieved significant price reductions when compared to prices in developed countries or to previous schemes involving TPV and BCV. However, the reductions achieved were insufficient and may compromise the universalization of access and the financial sustainability of the response to hepatitis C, especially with the possibility of a SUS funding freeze for 20 years 30 . It is worth highlighting that the change in therapeutic regimens meant that the estimated expenditure went from around R$ 412 million in 2014 to around R$ 945 million in 2015. Assuming that the purchase is a proxy for use, we estimate that this expenditure covered the treatment of around 30 thousand people. In Brazil, it is estimated that 1.4-1.7 million people are infected with HCV 31 . Assuming that 1.4 million of these people were eligible for the SOF + DAC association (US $ 8,732), the resource needed to treat them all would be US$12.2 billion or R $ 40.7 billion. In 2014, the total expenditure of the MoH with medicines was R$ 12.4 billion 32 . The scaling up treatment for chronic hepatitis C therefore depends on the MoH develop-ment of strategies that strength its bargaining power to negotiate price reductions for monopoly medicines.
After 2005, countries with manufacturing capacity to produce generic medicines had to comply with the TRIPS Agreement, which establishes patent protection for pharmaceutical products. In addition, multinational corporations, mostly patent holders, have entered into voluntary licensing agreements with Indian generic manufacturing companies, which have ensured market segmentation and have restricted access to the cheaper alternatives to a limited number of countries. Many middle-income countries, including Brazil, are unable to import thesecheaper alternatives generic versions 33 . Despite the difficulties and barriers mentioned above, it is possible to identify some options that the MoH could seek to stregthen its bargaining power when negotiating the prices of medicines under monopoly for viral hepatitis, as is illustrated by an analysis of the case sofosbuvir. The first step is to identify the patent barrier, ie what are the product patent applications filed in the country and analyze their patent status (pending or granted). According to the WHO patente landscape 34 , there are at least 21 patent claims applications related to sofosbuvir, of which at least five are filed in Brazil.
The next step is to qualitatively analyze the patent applications filed in order to screen those applications that actually cover the active principle ingredient (compound), production processes and available presentations, as well as to identify those that are just strategies to generate uncertainty around the product's patentability. The primary focus must be on the patent applications that can actually guarantee the exclusivity of the product purchased by SUS.
When the patent applications are pending a decision on whether or not to grant a patent, the MoH is able to import cheaper generic alternatives. If the option is to ensure more clarity as to whether or not to decide on patentability, two approaches can be implemented: the presentation of pre-grant oppositions (in Brazil is called "support to examination", according to article 31 of the Brazilian industrial property legislation), and the request for priority examination to the INPI, as established in Resolution 80/2013 of this body 35 . In 2015 and 2016, civil society organizations and national companies submitted oppositions related to patente applications for SOF in Brazil 36 . In 2016, the MoH requested priority examination of DAA patent applications, including those related to sofosbuvir.
If relevant patent applications are granted in the country, it is then appropriate to explore other options. From the perspective of industrial policy and local production efforts, one option is to use flexibilities such as "experimental use" and "Bolar exception" to obtain the registration (market authorization) for generic versions. This would enable the government to estimate production costs, have better references on the mark ups of the pharmaceutical companies, and to help the government in the issuing of compulsory licenses if price negotiations are not satisfactory 37 . This strategy can also be adopted while patent applications are pending decision.
Another strategy to be considered is the use of reference prices in the international market. These prices can be used by countries with the same level of relative development, for instance, Brazil could ask for the prices for SOF sold in Egypt and India. If the option to issue a compulsory license is used, it is important to identify international sources of the generic medicine which can be imported, as well as identifying capacity for local production by national public or private manufacturers. In 2016, Fiocruz announced a partnership with a consortium of national private companies for the development of sofosbuvir 38 . Considering the dynamics of incorporating new medicines into the SUS as well as the number of stakeholders with which the MoH has to establish price negotiations each year, the challenge is to build strategies that enable the government to strengthits bargaining power. It is opportune to identify the governmental institutions and stakeholders that can act in the different aspects of regulation of monopoly and price setting in order to contribute to the sustainability of the access to treatment for hepatites C in SUS 39 . The following examples are ilustrative of the role that diferent institutions can play in order to make relevant medicines available and affordable in the country. Anvisa could contribute to the regulation of entry prices (CMED) as well as to the mapping of patent applications and patent status and in the qualification of avalilable products in the international market in case importation is needed; the Oswaldo Cruz Foundation could contribute in the elaboration of patent oppositions (support to the examination) of relevant patent applications, as well as in the development of medicines, and to provide the MoH with estimates of cost of production; the MoH could request priority examination of the rele-vant product patent applications, as well as coordinate the different strategies involving governmental, non-governmental and private actors.
Some limitations of this analysis are: first, some selected medicines are also used for the treatment of hepatitis B, which may in turn make it difficult to accurately estimating the number of treatments; another issue concerns the currency exchange rate used. For imported products, such as the DAAs, the purchase contracts use different currency exchange rates that are only defined at the time of payment. Third, since the study is based on committed purchases and on contracted expenditure, exchange rate changes may have influenced the cost estimates. Fourth, the comparison with international prices was partially compromised by the fact that generic versions of simeprevir were not identified until the time of completion of the study, and only one source for generic version of daclatasvir was identified in 2016.
Final considerations
The study shows changes in the profile of MoH purchases for hepatitis C medicines, up to 2011, due to the incorporation of peginterferon alfa 2a and 2b, and afterwardsto the incorporation of new DAAs, which are more expensive medicines.If, on the one hand, new medicines have a better effectiveness profile than the previous options 12, 13 , on the other hand, the prices paid by the Brazilian MoH put at risk the possibility of treating everyone, compromising the principle of universal access under SUS. High drug prices should not be the justification for not treating everyone in need. Faced with this impasse, it is necessary for the country, that the MoH finds ways to deal with prices determinants that negatively impact on spending, by implementing a set of strategies to strengthen its bargaining power in price reduction negotiations, including addressing patent barriers and developing strategies for local production.
This analysis of expenditures and the estimated direct costs for the treatment of hepatitis C, provides an important basis for a more indepth analysis of the challenge faced in Brazil of increases in expenditures on medicines for SUS, increased burden of diseases and the pressure to incorporate innovative and monopoly technologies.
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